Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 20, Issue , 1990, Pages 205-219

  Harenberg, J ^a   Huck, K ^a   Bratsch, H ^a   Stehle, G ^a   Dempjie, C E ^a   Mall, K ^a   Blauth, M ^a   Usadel, K H ^a   Heene, D L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clinical trials; Duplex sonography; Heparin; Low molecular weight heparin; Phlebography; Thrombosis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; THROMBIN;

ADULT; AGED; BRAIN HEMORRHAGE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION TESTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; THROMBIN TIME; THROMBOPHLEBITIS;

EID: 0025678942     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000216179     Document Type: Article

References (47)

1. Kelton JG, Hirsh J: Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17: 259-291.
2. Harenberg J, De Vries JX: Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr 1983;261: 287-292.
3. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G: Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III. Biochem Biophys Res Commun 1983;116:492-499.
4. Barrowcliffe TW., Johnson EA, Egglcton CA. Thomas DP: Anticoagulant activities of lung and mucous heparins. Thromb Res 1977;12:27-36.
5. Bratt G, Tömebohm E, Widlund L, Lockner D: Low molecular weight heparin (Kabi 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986:42:613-620.
6. Harenberg J, Heene DL: Pharmacology and special clinical applications of low-molecular-weight heparins. Am J Hematol 1988;29:233-240.
7. Carter CJ. Kelton JG, Hirsh J. Cerskus A. Santos AV, Gent M: The relationship between the hemorrhagic and antithrombotic properties of two low molecular weight heparins in rabbits. Blood 1982: 59:1239-1245.
8. Thomas DP. Merton RE, Lewis WE, Barrowcliffe TW: Studies in man and experimental animals of low molecular weight heparin fraction. Thromb Haemost 1981;45:214-218.
9. Kakkar VV, Murray WJG: Efficacy and safety of low-molecular-weight heparin (CY 216) in preventing postoperative venous thromboembolism: A co-operative study. Br J Surg 1985;72:786-791.
10. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers P, Andrew M, Hull RD, Gent M: A randomized controlled trial of a low-molecular- weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986:315:925-929.
11. Encke A, Breddin K: Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988.75:1058-1063.
12. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM: Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986:16:159-164.
13. Turpie AGG, Levine MN, Hirsh J, Cater CJ, Jay RM, Powers PJ, Andrew M, Magnayni HN, Hull RD. Gent M: Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-526.
14. Barthels M, Poniewierski M, Kuhn M, Poliwoda H: Über die Wirksamkeit niedermolekularen Heparins (Fragmin®) in der Thromboembolieprophylaxe bei internistischen Patienten. Med Klin 1988;83:241-245.
15. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJH: Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin®) in stroke patients. Haemostasis 1989;19:245-250.
16. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kiibler W, Heene DL: Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990:3, in press.
17. Harenberg J, Leber G, Augustin R, Raedsch R, Schwartz F, Stiehl A, Zimmermann R: Long-term prophylaxis of thromboembolism with low molecular weight heparin. Klin Wochenschr 1987;65: 331-337.
18. Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kiibler W: Long-term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants. Nouv Rev Fr Hématol 1988;31:363-369.
19. White EM: Duplex sonography of the lower extremity venous system; in Grant EG, White EM (eds): Duplex Sonography. New York, Springer, 1988.
20. Rabinov K, Paulin S: Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144.
21. Biello DR. Mattar AG, McNight RC, Siegal BA: Interpretation of ventilation-perfusion studies in patients with suspected pulmonary embolism. AJR 1979;133:1033-1037.
22. Marder VJ, Soulen RL, Atichartakran V, Bud-zynski AZ, Parulekar S, Edward KN. Zahavi J, Algazy KM: Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977;89:1018-1029.
23. Harenberg J, Giese C, Knödler A, Zimmermann R: Anti-factor Xa clotting method for heparin and low molecular weight heparins. Ärztl Lab 1986; 32:181-184.
24. Harenberg J. Modified anti-factor Xa chromo- genic substrate assay for heparin and low molecular weight heparins. Ärztl Lab 1987;33:39-41.
25. Harenberg J, Giese C, Knödler A, Zimmermann R: Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis 1989;19:13-20.
26. Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL: Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost 1989;61:357-362.
27. Hirsh J, Van Aken W, Gallus AS. Dollery CT, Cade JF, Yung WL: Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-695.
28. Denton J. Lane DA, Thunberg L, Slater AM, Lindahl U: Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983;209:455-460.
29. Hull RD, Raskob GE, Hirsh J, Jay RM, Ledere JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of prox- imal-vein thrombosis. N Engl J Med 1986:315: 1109-1114.
30. Albada J, Nieuwenhuis HK, Sixma JJ: Treatment of acute vein thromboembolism with low-molecular-weight heparin (Fragmin). Circulation 1989; 80:935-940.
31. Harenberg J, Gnasso A, De Vries JX, Zimmer- mann R, Augustin J: Anticoagulation and lipolytic effects of a low molecular weight heparin fraction. Thromb Res 1985;39:683-692.
32. Harenberg J, Würzner B, Zimmermann R, Schettler G: Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 1986;44:549-554.
33. Harenberg J, Stehle G, Augustin J, Zimmermann R: Comparative human pharmacology of low molecular weight heparins. Semin Thromb Hemost 1989;15:414-422.
34. Basu D, Gallus A, Hirsh J, Cade JA: Prospective study of value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-327.
35. Teien AN, Lie M: Heparin assay in plasma: A comparison of five clotting methods. Thromb Res 1975;7:777-788.
36. Holm HA, Abildgaard U: Heparin treatment of deep venous thrombosis: Correlation between clinical effects and heparin assays; in Witt I (ed): Heparin - New Biochemical and Medical Aspects. Berlin, de Gruyter, 1982, pp. 289-300.
37. Villain P. Bouvier JL, Le Corff G, Elias A, Juhan- Vague I, Serradimigni A: Do apTT and anti Ila activity permit the prediction of the efficiency of heparin therapy in patients with proximal deep vein thrombosis? Thromb Haemost 1987;58: 1372.
38. Samama M: Correlation between anti-Xa activity and occurrence of DVT and haemorrhage in post- surgical patients treated with either logiparin (LMWH) or standard heparin (abstract). Thromb Haemost 1989;62:1470.
39. Bratt G, Tömebohm E, Granqvist S, Aberg W, Lockner DA: Comparison between low-molecular-weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813-817.
40. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel B, Sortland O, Vinje B: Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16:30-37.
41. Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, Hedner U: Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 1989:55: 767-778.
42. Janvier G, Winnock S, Dugrais G, Vallet A. Dar- del E, Serisé JM, Calen S, Vergncs C, Toulemonde F: Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222). Haemostasis 1987;7:49-58.
43. Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, Toulemonde F, Bassand JP, Maurat JP: Un nouveau traitement des thromboses vei- neuses profondes: Les fractions d’héparine de bas poids moléculaire. Presse Méd 1988;17:197-200.
44. Huet Y, Gonault-Heilmann M, Contant G. Brun- Buisson C: Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study. Intensive Care Med 1987; 13: 126-130.
45. Bakker M, Dekker PJ, Knot EAR, Van Bergen PFMM. Jonker JJC: Home treatment for deep venous thrombosis with low-molecular-weight heparin. Lancet 1988;2: 1142.
46. Marciniak E, Gockerman JP: Heparin-induced decrease in circulating antithrombin III. Lancet 1977;1:581-584.
47. Dukes GE, Sanders SW. Russo J, Swenson E, Bur- nakis TG, Saffle JR, Warden GD: Transaminase elevations in patients receiving bovine or porcine heparin. Ann Intern Med 1984;100:646-650.